Kariya Pharmaceuticals ApS: Financial statements 2024
CVR: 39270684
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
Kariya Pharmaceuticals ApS (CVR 39270684) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK -3,624,681 and a net result of DKK -2,599,412 compared with DKK -8,022,549 the year before. Equity in the 2024 report amounted to DKK 1,283,672. The solvency ratio was 55.7%. The company had 1 employee in the financial year.
- Gross Profit
- DKK -3,624,681
- Profit/Loss
- DKK -2,599,412
- Equity
- DKK 1,283,672
- Total Assets
- DKK 2,303,648
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | -3.6 mio. | -2.6 mio. | 1.3 mio. | 1 |
| 2023 | - | -10.2 mio. | -8 mio. | -6.4 mio. | 1 |
| 2022 | - | -13.8 mio. | -14 mio. | -26.7 mio. | 1 |
| 2021 | - | -2.7 mio. | -3.3 mio. | -12.7 mio. | 1 |
| 2020 | - | -1.5 mio. | -2.2 mio. | -9.5 mio. | 2 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
Kariya Pharmaceuticals ApS has published its annual report for 2023. Gross profit came to DKK -10,223,064, and the net result was DKK -8,022,549.
About Kariya Pharmaceuticals ApS
Kariya Pharmaceuticals ApS is a Danish company of the type Anpartsselskab based in København N, founded in 2018. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named Kariya Pharmaceuticals IVS. The management consists of Christian Hölscher. The board consists of Ian Rodney Laquian (chair), Christian Hölscher, Claus Elsborg Olesen and John Connell. The company's owners include JUMIKA Holdings ApS, Thomsen Pharma ApS and MAC Clinical Research Finance Ltd.. The company has 0 employees (2025). In 2025, the company reported a gross profit of DKK -32,093,186 and a net result of DKK -26,490,250 compared with DKK -2,599,412 the year before. Equity in the 2025 report amounted to DKK -25,206,578.